T helper 17 (Th17) cells and related cytokines are important in multiple sclerosis (MS), which have become the new therapeutic targets of MS. In published studies, the effect of interferon-β (IFN-β) on the proportion of Th17 cells and related cytokines in MS patients remains controversial. We did a meta-analysis to assess the role of IFN-β on Th17 cells and related cytokines in MS patients. Compared with control subjects, MS patients with IFN-β treatment had a lower proportion of Th17 cells in CD4+ T cells of peripheral blood [-1.49 (-2.96 to -0.02)], interleukin (IL)-17 level [-1.08 (-1.77 to -0.40)], and IL-23 level [-1.63 (-2.59 to -0.68)] in serum. The results showed that IFN-β can reduce the proportion of Th17 cells, the levels of IL-17 and IL-23 in serum of MS.

中文翻译：

---

干扰素-β治疗对多发性硬化症中T辅助17细胞和相关细胞因子比例的影响：荟萃分析。

T辅助17（Th17）细胞和相关的细胞因子在多发性硬化症（MS）中很重要，多发性硬化症已成为MS的新治疗靶标。在已发表的研究中，干扰素-β（IFN-β）对MS患者Th17细胞和相关细胞因子比例的影响仍存在争议。我们进行了荟萃分析，以评估IFN-β在MS患者中对Th17细胞和相关细胞因子的作用。与对照组相比，接受IFN-β治疗的MS患者外周血CD4 + T细胞中Th17细胞的比例较低[-1.49（-2.96至-0.02）]，白介素（IL）-17水平较低[-1.08（-血清中的IL-23水平[-1.63（-2.59至-0.68）]（1.77至-0.40）]和IL-23水平[-1.63（-2.59至-0.68）]。结果表明，IFN-β可降低MS血清中Th17细胞比例，IL-17和IL-23水平。